|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3507-3516.
Prepublished online as a Blood First Edition Paper on August 20, 2007; DOI 10.1182/blood-2007-06-097238.
 Previous Article | Next Article 
Submitted June 29, 2007
Accepted July 25, 2007
The role of FDG-PET scans in patients with lymphoma
Pamela Seam, Malik E. Juweid, and Bruce D. Cheson*
Medicine Branch, National Cancer Institute, Bethesda, MD, United States
Department of Radiology, University of Iowa, Iowa City, IA, United States
Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC, United States
* Corresponding author; email: bdc4{at}georgetown.edu.
18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is a non-invasive, 3-dimensional imaging modality that has become widely used in the management of patients with malignant lymphomas. This technology has been demonstrated to be more sensitive and specific than either 67gallium scintigraphy or computerized tomography, providing a more accurate distinction between scar or fibrosis and active tumor. PET scans have been evaluated in pretreatment staging, restaging, monitoring during therapy, post-therapy surveillance, assessment of transformation and, more recently, as a surrogate marker in new drug development. Data to support these various roles requires prospective validation. Moreover, caution must be exercised in the interpretation of PET scans because of technical limitations, variability of FDG-avidity among the different lymphoma histologic subtypes, and in the large number of etiologies of false-negative and false-positive results. Recent attempts to standardize PET in clinical trials, and incorporation of this technology into uniformly adopted response criteria will hopefully lead to improved outcome for patients with lymphoma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
J. Clin. Oncol.,
April 10, 2009;
27(11):
1906 - 1914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Cheson
The Case Against Heavy PETing
J. Clin. Oncol.,
April 10, 2009;
27(11):
1742 - 1743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Buck, M. Bommer, M. E. Juweid, G. Glatting, S. Stilgenbauer, F. M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Moller, et al.
First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine
J. Nucl. Med.,
November 1, 2008;
49(11):
1756 - 1762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Elstrom, J. P. Leonard, M. Coleman, and R. K. J. Brown
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
Ann. Onc.,
October 1, 2008;
19(10):
1770 - 1773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill
Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
Haematologica,
March 1, 2008;
93(3):
471 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?
J. Nucl. Med.,
January 1, 2008;
49(1):
9 - 12.
[Full Text]
[PDF]
|
|
|
|
|
